Skip to main content
KYUNG NAM PHARM.CO.,LTD. logo

KYUNG NAM PHARM.CO.,LTD. — Investor Relations & Filings

Ticker · 053950 ISIN · KR7053950002 KO Manufacturing
Open in API
Filings indexed 428 across all filing types
Latest filing 2025-01-22 Capital/Financing Update
Country KR South Korea
Listing KO 053950

About KYUNG NAM PHARM.CO.,LTD.

https://www.kyungnampharm.com:6519/eng/

Kyung Nam Pharm is a pharmaceutical company established in 1957 that specializes in over-the-counter (OTC) medicines and health functional foods. The company is widely known for its flagship brand, Lemona, which was the first powdered Vitamin C product in its domestic market and is now marketed as an inner-beauty product. The core product portfolio also includes PM, a topical treatment for athlete's foot, and Minol F Troche for sore throats. A key area of specialization is human placenta-based medicines; the company was a pioneer in developing and commercializing human placenta drink formulations. Kyung Nam Pharm focuses on developing accessible healthcare solutions based on its corporate philosophy of promoting human health.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the acquisition of convertible bonds before maturity (Call Option exercise). This type of filing relates to capital structure and financing activities, specifically the repurchase of debt instruments. It fits the 'Capital/Financing Update' (CAP) category as it details the company's financial management of its outstanding convertible bonds.
2025-01-22 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Kyungnam Pharm) regarding the 'Adjustment of Conversion Price' (전환가액의조정) for convertible bonds. This type of filing is a standard disclosure related to capital structure changes and financial instruments. Since it specifically details the adjustment of conversion prices for existing debt instruments, it falls under the 'Capital/Financing Update' category.
2025-01-10 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. It details changes in share ownership (specifically convertible bonds) by Sangsangin Savings Bank and its affiliate in Kyungnam Pharmaceutical. This type of filing is a standard regulatory disclosure for significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2025-01-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of convertible bonds by a major shareholder and its special related parties, specifically mentioning the change in shareholding status and the purpose of the holding (influencing management). This falls under the category of Major Shareholding Notification (MRQ).
2024-12-13 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement from Kyungnam Pharm regarding the setting of a record date and shareholder register closure period for their upcoming 27th Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal notice of a corporate action related to shareholder rights. Given the nature of the announcement and its brevity, it fits best under the general regulatory filing category.
2024-12-13 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the adjustment of the conversion price for convertible bonds (CB). It details the specific changes in conversion price, the number of shares, and the underlying reasons (market price decline). This falls under capital structure changes and financing updates, specifically categorized as a Capital/Financing Update (CAP) in the provided schema.
2024-12-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.